# TriLinc Global Impact Fund LLC: financial statements, quarterly

TRLC · OTC · CIK 1550453 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trlc.md) · [Financials](/companies/trlc/financials.md) · [Filings](/companies/trlc/filings.md) · [Insiders](/companies/trlc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trlc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating income | $m | [2.1](/filings/0001437749-24-035226.md) | [(6.5) d](/filings/0001437749-25-009799.md) | [3.2](/filings/0001437749-25-016380.md) | [2.0](/filings/0001437749-25-026841.md) | [3.3](/filings/0001437749-25-035135.md) | [3.8 d](/filings/0001437749-26-010358.md) | [3.1](/filings/0001437749-26-017091.md) | [3.7](/filings/0001437749-26-027238.md) | [(0.5)](/filings/0001437749-25-035135.md) | [(1.4) d](/filings/0001437749-26-010358.md) | [0.5](/filings/0001437749-26-017091.md) | [2.5](/filings/0001437749-26-027238.md) |
| Net income | $m | [1.0](/filings/0001437749-24-035226.md) | [1.5 d](/filings/0001437749-25-009799.md) | [3.1](/filings/0001437749-25-016380.md) | [3.4](/filings/0001437749-25-026841.md) | [3.5](/filings/0001437749-25-035135.md) | [2.4 d](/filings/0001437749-26-010358.md) | [2.6](/filings/0001437749-26-017091.md) | [0.7](/filings/0001437749-26-027238.md) | [(11.1)](/filings/0001437749-25-035135.md) | [(0.7) d](/filings/0001437749-26-010358.md) | [0.1](/filings/0001437749-26-017091.md) | [(0.8)](/filings/0001437749-26-027238.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [0.02](/filings/0001437749-24-035226.md) | not reported | [0.06](/filings/0001437749-25-016380.md) | [0.07](/filings/0001437749-25-026841.md) | [0.07](/filings/0001437749-25-035135.md) | not reported | [0.05](/filings/0001437749-26-017091.md) | [0.02](/filings/0001437749-26-027238.md) | [(0.23)](/filings/0001437749-25-035135.md) | not reported | [0.00](/filings/0001437749-26-017091.md) | [(0.02)](/filings/0001437749-26-027238.md) |

- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.3](/filings/0001437749-23-032651.md) | [1.0](/filings/0001437749-25-009799.md) | [2.1](/filings/0001437749-24-016496.md) | [1.1](/filings/0001437749-24-026450.md) | [0.9](/filings/0001437749-24-035226.md) | [0.1](/filings/0001437749-26-010358.md) | [1.1](/filings/0001437749-25-016380.md) | [0.1](/filings/0001437749-25-026841.md) | [0.0](/filings/0001437749-25-035135.md) | [0.1](/filings/0001437749-26-027238.md) | [1.1](/filings/0001437749-26-017091.md) | [0.4](/filings/0001437749-26-027238.md) |
| Total assets | $m | [284](/filings/0001437749-23-032651.md) | [279](/filings/0001437749-25-009799.md) | [277](/filings/0001437749-24-016496.md) | [281](/filings/0001437749-24-026450.md) | [283](/filings/0001437749-24-035226.md) | [286](/filings/0001437749-26-010358.md) | [288](/filings/0001437749-25-016380.md) | [293](/filings/0001437749-25-026841.md) | [283](/filings/0001437749-25-035135.md) | [283](/filings/0001437749-26-027238.md) | [283](/filings/0001437749-26-017091.md) | [283](/filings/0001437749-26-027238.md) |
| Total liabilities | $m | [9.1](/filings/0001437749-23-032651.md) | [5.9](/filings/0001437749-25-009799.md) | [5.5](/filings/0001437749-24-016496.md) | [5.5](/filings/0001437749-24-026450.md) | [4.0](/filings/0001437749-24-035226.md) | [4.5](/filings/0001437749-26-010358.md) | [4.8](/filings/0001437749-25-016380.md) | [8.5](/filings/0001437749-25-026841.md) | [9.5](/filings/0001437749-25-035135.md) | [10.2](/filings/0001437749-26-027238.md) | [10.8](/filings/0001437749-26-017091.md) | [10.9](/filings/0001437749-26-027238.md) |
| Long-term debt | $m | [0.0](/filings/0001437749-23-032651.md) | [0.0](/filings/0001437749-24-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.9 d](/filings/0001437749-24-035226.md) | [4.0 d](/filings/0001437749-25-009799.md) | [5.3](/filings/0001437749-25-016380.md) | [(1.0) d](/filings/0001437749-25-026841.md) | [(0.2) d](/filings/0001437749-25-035135.md) | [(0.8) d](/filings/0001437749-26-010358.md) | [1.0](/filings/0001437749-26-017091.md) | [(1.0) d](/filings/0001437749-26-027238.md) | [(0.1) d](/filings/0001437749-25-035135.md) | [0.1 d](/filings/0001437749-26-010358.md) | [1.1](/filings/0001437749-26-017091.md) | [(0.7) d](/filings/0001437749-26-027238.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [47.2](/filings/0001564590-22-029294.md) | [47.4](/filings/0001564590-22-037596.md) | [47.7](/filings/0001564590-22-029294.md) | [47.7](/filings/0001564590-22-037596.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 0 at 2016-09-30, from the cover of the [10-Q filed 2016-11-14](/filings/0001564590-16-029214.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.